Treatment against leukemia
Text created by automatic translator Elia and has not been subsequently revised by translators. Elia Elhuyar
The European Commission approves a new treatment against chronic leukemia: Monoclonal Antibody Macycampath™. Invented by scientists from the Universities of Oxford and Cambridge, it serves to treat the most common type of leukemia in adults, i.e. chronic B-cell leukemia. With this treatment, the antibody is first associated with a specific cancer white cell antigen, which is removed from the blood, bone marrow, and organs.
Zu idazle
Zientzia aldizkaria
